AstraZeneca is moving into the field of self-amplifying RNA via a deal with VaxEquity, with the goal of developing a next generation vaccines and therapeutics platform more potent than the Pfizer/BioNTech and Moderna pioneering messenger RNA (mRNA) vaccines.
The new partners have their sights set on a broad range of potential vaccine and therapeutic targets, with AstraZeneca seeing...